AMIKACIN SULFATE

Post-LOE

amikacin sulfate

Bristol Myers Squibb

ANDAINJECTIONINJECTABLE

Approved

Mar 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

AMIKACIN SULFATE (amikacin sulfate) by Bristol Myers Squibb is mechanism of action amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. Approved for the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli and 12 more indications. First approved in 2024.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria.

Indications (15)

the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria including Pseudomonas species

Worked on AMIKACIN SULFATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.